FORM 4

Check this box if no
longer subject to Section
16. Form 4 or Form 5
obligations may continue.
See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

^{ue.} Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting P RA CAPITAL MANAGEME	2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner			
(Last) (First) 200 BERKELEY STREET, 1	(Middle) BTH FLOOR,	3. Date of Earliest T 02/04/2021	3. Date of Earliest Transaction (Month/Day/Year) 02/04/2021					Officer (give title below) Othe	r (specify below)
(Street) BOSTON, MA 02116	4. If Amendment, D	ate Original I	iled(N	Ionth/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person				
(City) (State)	(Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1.Title of Security 2. Transaction Date (Month/Day/Yea			(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form:	Beneficial
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Ordinary Shares	02/04/2021		С		11,651,597	А	<u>(1)</u>	11,651,597	Ι	See Footnotes (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this SEC 1474 (9-02) form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
Security (Instr. 3)	Conversion	e (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code		5. Number of Derivative		6. Date Exercisable and Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(I) (Instr. 4)	
6.500% Exchangeable Senior Subordinated Note due 2025	<u>(1)</u>	02/04/2021		С			8,486,000 (<u>1)</u>	01/21/2021	01/31/2025	Ordinary Shares	11,651,597	<u>(1)</u>	0	Ι	See Footnotes (2)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
RA CAPITAL MANAGEMENT, L.P. 200 BERKELEY STREET, 18TH FLOOR BOSTON, MA 02116		Х				
RA Capital Healthcare Fund LP 200 BERKELEY STREET, 18TH FLOOR BOSTON, MA 02116		Х				
Kolchinsky Peter C/O RA CAPITAL MANAGEMENT, L.P. 200 BERKELEY STREET, 18TH FLOOR BOSTON, MA 02116		Х				
Shah Rajeev M. C/O RA CAPITAL MANAGEMENT, L.P. 200 BERKELEY STREET, 18TH FLOOR BOSTON, MA 02116		Х				

Signatures

/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	02/08/2021
Signature of Reporting Person	Date

/s/ Peter Kolchinsky, Manager of RA Capital Healthcare GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.	02/08/2021
Signature of Reporting Person	Date
/s/ Peter Kolchinsky	02/08/2021
**Signature of Reporting Person	Date
/s/ Rajeev Shah	02/08/2021
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) RA Capital Healthcare Fund, L.P. (the "Fund") held \$8,486,000 principal amount of the Issuer's 6.500% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior Subordinated Notes due 2025, which became exchangeable into the Issuer's 6.700% Exchangeable Senior S
- RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter (2) Kolchinsky and Mr. Rajeev Shah are the managing members. The securities reported on this Form 4 are held directly by the Fund. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.